Claims for Patent: 6,699,871

Summary for Patent: 6,699,871

Title:	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Abstract:	The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s):	Scott D. Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm MacCoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US10/189,603
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,699,871
Patent Claims:	1. A compound of the formula I: wherein: Ar is phenyl which is unsubstituted or substituted with 1-5 of R3, wherein R3 is independently selected from the group consisting of: (1) halogen, (2) C1-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, (3) OCl-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens, and (4) CN; X is selected from the group consisting of: (1) N, and (2) CR2; R1 and R2 are independently selected from the group consisting of: (1) hydrogen, (2) CN, (3) C1-10alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 halogens or phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R4, OR4, NHSO2R4, SO2R4, CO2H, and CO2C1-6alkyl, wherein the CO2Cl-6alkyl is linear or branched, (4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R4, OR4, NHSO2R4, SO2R4, CO2H, and CO2C1-6alkyl, wherein the CO2C1-6alkyl is linear or branched, and (5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, OH, halogen, C1-6alkyl, and OC1-6alkyl, wherein the C1-6alkyl and OC1-6alkyl are linear or branched and optionally substituted with 1-5 halogens; R4 is C1-6alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO2H, and CO2C1-6alkyl, wherein the CO2C1-6alkyl is linear or branched; and pharmaceutically acceptable salts thereof and individual diastereomers thereof. 2. The compound of claim 1 of the formula Ia: wherein X, Ar and R1 are defined in claim 1; and pharmaceutically acceptable salts and individual diastereomers thereof. 3. The compound of claim 1 of the formula Ib: wherein Ar and R1 are defined in claim 1; and pharmaceutically acceptable salts and individual diastereomers thereof. 4. The compound of claim 1 of the formula Ic: wherein Ar, R1 and R2 are defined in claim 1; and pharmaceutically acceptable salts thereof and individual diastereomers thereof. 5. The compound of claim 1 wherein Ar is phenyl which is unsubstituted or substituted with 1-5 substitutents which are independently selected from the group consisting of: (1) fluoro, (2) bromo, and (3) CF3. 6. The compound of claim 1 wherein Ar is selected from the group consisting of: (1) phenyl, (2) 2-fluorophenyl, (3) 3,4-difluorophenyl, (4) 2,5-difluorophenyl, (5) 2,4,5-trifluorophenyl, (6) 2-fluoro-4-(trifluoromethyl)phenyl, and (7) 4-bromo-2,5-difluorophenyl. 7. The compound of claim 1 wherein R1 is selected from the group consisting of: (1) hydrogen, and (2) C1-6alkyl, which is linear or branched and which is unsubstituted or substituted with phenyl or 1-5 fluoro. 8. The compound of claim 1 wherein R1 is selected from the group consisting of: (1) hydrogen, (2) methyl, (3) ethyl, (4) CF3, (5) CH2CF3, (5) CF2CF3, (6) phenyl, and (7) benzyl. 9. The compound of claim 1 wherein R1 is selected from the group consisting of: (1) hydrogen, (2) methyl, (3) ethyl, (4) CF3, and (5) CH2CF3. 10. The compound of claim 1 wherein R1 is hydrogen or CF3. 11. The compound of claim 1 wherein R2 is selected from: (1) hydrogen, (2) C1-6alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 fluoro and (3) phenyl, which is unsubstituted or substituted with 1-3 substituents independently selected from fluoro, OCH3, and OCF3. 12. The compound of claim 1 wherein R2 is selected from the group consisting of: (1) hydrogen, (2) methyl, (3) ethyl, (4) CF3, (5) CH2CF3, (5) CF2CF3, (6) phenyl, (7) (4-methoxy)phenyl, (8) (4-trifluoromethoxy)phenyl, (9) 4-fluorophenyl, and (10) 3,4-difluorophenyl. 13. The compound of claim 1 wherein R2 is CF3 or CF2CF3. 14. The compound of claim 1 wherein R3 is F, Br or CF3. 15. A compound which is selected from the group consisting of: or a pharmaceutically acceptable salts thereof. 16. A compound which is: or a pharmaceutically acceptable salt thereof. 17. A compound which is: or a pharmaceutically acceptable salt thereof. 18. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1. 19. A pharmaceutical composition which comprises an inert carrier and a compound of claim 16. 20. A pharmaceutical composition which comprises an inert carrier and a compound of claim 16. 21. A method for inhibition of dipeptidyl peptidase-IV enzyme activity in a mammal in need thereof which comprises the administration to the mammal of an effective amount of a compound of claim 1. 22. A method for treating or controlling diabetes in a mammalian patient in need thereof comprising the administration to a patient of an effective amount of a compound of claim 1. 23. A method for treating or controlling non-insulin dependent (Type 2) diabetes mellitus in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1. 24. A method for treating or controlling hyperglycemia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1. 25. A method for treating or controlling obesity in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1. 26. A method for treating or controlling one or more lipid disorders selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1.